HRP20090074T3 - 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses - Google Patents

3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Info

Publication number
HRP20090074T3
HRP20090074T3 HR20090074T HRP20090074T HRP20090074T3 HR P20090074 T3 HRP20090074 T3 HR P20090074T3 HR 20090074 T HR20090074 T HR 20090074T HR P20090074 T HRP20090074 T HR P20090074T HR P20090074 T3 HRP20090074 T3 HR P20090074T3
Authority
HR
Croatia
Prior art keywords
cis
treatment
dihydrotetrabanezine
psychoses
schizophrenia
Prior art date
Application number
HR20090074T
Other languages
English (en)
Croatian (hr)
Inventor
John Duffield Andrew
Elisabeth Yarrow Jean
Original Assignee
Cambridge Laboratories (Ireland) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by Cambridge Laboratories (Ireland) Limited filed Critical Cambridge Laboratories (Ireland) Limited
Publication of HRP20090074T3 publication Critical patent/HRP20090074T3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20090074T 2005-08-06 2006-08-04 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses HRP20090074T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds
PCT/GB2006/002936 WO2007017654A1 (en) 2005-08-06 2006-08-04 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Publications (1)

Publication Number Publication Date
HRP20090074T3 true HRP20090074T3 (en) 2009-04-30

Family

ID=37400949

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090074T HRP20090074T3 (en) 2005-08-06 2006-08-04 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Country Status (20)

Country Link
US (1) US20110257220A1 (OSRAM)
EP (2) EP1855677B1 (OSRAM)
JP (1) JP2009504622A (OSRAM)
KR (1) KR20080033500A (OSRAM)
AT (2) ATE534391T1 (OSRAM)
AU (1) AU2006277753B2 (OSRAM)
CA (1) CA2620960A1 (OSRAM)
CY (1) CY1108843T1 (OSRAM)
DE (1) DE602006004009D1 (OSRAM)
DK (1) DK1855677T3 (OSRAM)
ES (1) ES2318771T3 (OSRAM)
HR (1) HRP20090074T3 (OSRAM)
MX (1) MX2008001549A (OSRAM)
NZ (1) NZ566011A (OSRAM)
PL (1) PL1855677T3 (OSRAM)
PT (1) PT1855677E (OSRAM)
RS (1) RS50807B (OSRAM)
RU (1) RU2407743C2 (OSRAM)
SI (1) SI1855677T1 (OSRAM)
WO (1) WO2007017654A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
US7897768B2 (en) 2007-06-08 2011-03-01 General Electric Company Method for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
WO2011153157A2 (en) 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
KR101882044B1 (ko) 2011-04-01 2018-07-25 쓰리엠 이노베이티브 프로퍼티즈 캄파니 트라이아진계 자외선 흡수제를 포함하는 필름
MX2016009817A (es) 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
CN113368110A (zh) 2014-02-07 2021-09-10 纽罗克里生物科学有限公司 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
ES2972600T3 (es) 2015-10-30 2024-06-13 Neurocrine Biosciences Inc Sales de diclorhidrato de valbenazina y polimorfos de las mismas
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
TW202515564A (zh) * 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
JP7199359B2 (ja) 2017-01-27 2023-01-05 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
BR112020005373A2 (pt) 2017-09-21 2020-09-24 Neurocrine Biosciences Inc. formulação de valbenazina em alta dosagem e composições, métodos e kits relacionados com valbenazina
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
SG11202003194YA (en) 2017-10-10 2020-05-28 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US2843591A (en) 1958-07-15 Method for preparing same
CA2058640A1 (en) * 1991-01-25 1992-07-26 Richard R. Scherschlicht Tricyclic pyridone derivative
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2770215B1 (fr) * 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
JP2009504622A (ja) 2009-02-05
CY1108843T1 (el) 2014-07-02
RU2407743C2 (ru) 2010-12-27
WO2007017654A1 (en) 2007-02-15
EP1855677B1 (en) 2008-12-03
ATE415968T1 (de) 2008-12-15
PT1855677E (pt) 2009-01-13
DK1855677T3 (da) 2009-02-09
SI1855677T1 (sl) 2009-04-30
AU2006277753B2 (en) 2011-11-10
NZ566011A (en) 2011-01-28
EP2050451B1 (en) 2011-11-23
ATE534391T1 (de) 2011-12-15
EP2050451A1 (en) 2009-04-22
KR20080033500A (ko) 2008-04-16
US20110257220A1 (en) 2011-10-20
DE602006004009D1 (de) 2009-01-15
HK1111083A1 (en) 2008-08-01
EP1855677A1 (en) 2007-11-21
RS50807B (sr) 2010-08-31
PL1855677T3 (pl) 2009-07-31
ES2318771T3 (es) 2009-05-01
AU2006277753A1 (en) 2007-02-15
CA2620960A1 (en) 2007-02-15
RU2008108623A (ru) 2009-09-20
MX2008001549A (es) 2008-04-04

Similar Documents

Publication Publication Date Title
HRP20090074T3 (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
MY135233A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
MX2007004179A (es) Derivados de triazolpiridina como agentes antibacterianos.
MX2010004576A (es) Derivados de pirimidina novedosos.
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
TW200700406A (en) Novel thiophene derivatives
ZA200807274B (en) Novel pyridine derivatives
TW200716591A (en) Novel thiophene derivatives
MY154909A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
TW200716552A (en) Novel thiophene derivatives
MXPA05010000A (es) Derivados de p-diaminobenceno substituidos.
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
TW200738670A (en) Novel thiophene derivatives
ZA200703309B (en) Compositions for use against one or more pathogens
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
GEP20115201B (en) Cinnamoyl-piperazine derivatives and their use as par- i antagonists
MX2009012117A (es) Composiciones y derivados heterociclicos sustituidos y su uso farmaceutico como antibacterianos.
MY149705A (en) Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof
JO2578B1 (en) Compounds Theophene benzimidazole
TW200942524A (en) Novel aminomethyl benzene derivatives
IL200469A0 (en) Benzimidazole derivatives
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
TW200630367A (en) Substituted adenines and the uses thereof